Clinical evolution and mortality of critically ill patients with SARS-CoV-2 pneumonia treated with remdesivir in an adult intensive care unit of Paraguay.

Jessica FigueredoLorena Fontclara LopezBelinda Figueredo LeguizamonMargarita SamudioMarcelo PederzaniFederico Fretes ApeltPatricia AñazcoRicardo CaballeroHugo Bianco

Published in: BMC infectious diseases (2024)

Critically ill patients with SARS-CoV-2 pneumonia treated with remdesivir had a lower risk of death and need for mechanical ventilation and develop less ARDS as compared to the control group. No differences were found in the presentation of adverse effects.

Keyphrases

mechanical ventilation
sars cov
intensive care unit
respiratory failure
acute respiratory distress syndrome
respiratory syndrome coronavirus
extracorporeal membrane oxygenation
cardiovascular events
newly diagnosed
cardiovascular disease
community acquired pneumonia